Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
<p><strong>Objectives</strong></p><p>Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the mi...
Principais autores: | Coates, L, Rahman, P, Psaradellis, E, Rampakakis, E, Osborne, B, Lehman, A, Nantel, F |
---|---|
Formato: | Journal article |
Publicado em: |
Oxford University Press
2018
|
Registros relacionados
-
Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Emmanouil Rampakakis, et al.
Publicado em: (2020-08-01) -
Golimumab for the treatment of psoriatic arthritis
por: H Yang, et al.
Publicado em: (2011-05-01) -
Golimumab in the treatment of psoriatic arthritis: efficacy and safety
por: Tatiana Viktorovna Korotaeva, et al.
Publicado em: (2015-09-01) -
Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Proton Rahman, et al.
Publicado em: (2020-09-01) -
Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
por: M. Rossini, et al.
Publicado em: (2015-03-01)